论文部分内容阅读
目的研究乳腺癌多药耐药细胞人类白细胞抗原(HLA)和免疫共刺激分子B7-1(CD80)、B7-2(CD86)表达的可调控性。方法应用免疫荧光FITC-抗体直接标记的流式细胞检测技术(FCM)检测乳腺癌多药耐药细胞MCF-7/ADR经重组人干扰素-α2b(rhIFN-α2b)不同浓度(0、100、400、800IU/ml)和不同作用时间(0、12、24和48h)处理后HLA和B7表达及其变化。结果rhIFN-α2b在浓度小于1×103 IU/ml时对MCF-7/ADR细胞生长和增值无明显影响。经rhIFN-α2b(400IU/ml)处理,MCF-7/ADR细胞HLA和B7表达的阳性细胞百分率(PECR)有不同程度升高,以24h时比较明显。当不同浓度rhIFN-α2b(100、400、800IU/ml)处理24h后,MCF-7/ADR细胞HLA-Ⅰ表达的PECR由未处理时的(76.26±7.55)%升至(78.12±8.34)%、(87.84±12.45)%、(83.98±10.37)%(P<0.05);HLA-DR由未处理时的(13.92±5.23)%升至(24.26±9.02)%、(31.48±6.33)%、(30.00±4.68)%(P<0.005);B7-1变化不明显,分别为(2.42±1.28)%、(1.91±2.71)%、(3.33±3.92)%和(2.62±1.27)%(P>0.05);B7-2由未处理时的(1.28±0.81)%升至(3.01±2.44)%、(4.62±2.81)%和(8.68±4.45)%(P<0.05)。平均相对荧光强度(RLFI)以HLA-Ⅰ变化最为明显,由未处理时的57.77±7.55升至79.29±8.34、79.85±10.23和89.85±12
Objective To study the regulation of human leukocyte antigen (HLA) and immune co-stimulatory molecules B7-1 (CD80) and B7-2 (CD86) expression in breast cancer multidrug resistance cells. Methods The expression of rhIFN-α2b in breast cancer multi-drug resistant cell line MCF-7 / ADR was detected by flow cytometry (FCM) with FITC- 400,800 IU / ml) and different time (0, 12, 24 and 48h) after treatment of HLA and B7 expression and changes. Results When rhIFN-α2b concentration was less than 1 × 103 IU / ml, the proliferation and proliferation of MCF-7 / ADR cells were not significantly affected. The percentage of positive cells (PECR) in MCF-7 / ADR cells treated with rhIFN-α2b (400IU / ml) increased to some extent, especially at 24h. After treated with different concentrations of rhIFN-α2b (100,400,800 IU / ml) for 24 h, the PECR of HLA-Ⅰ expression in MCF-7 / ADR cells increased from (76.26 ± 7.55)% to (78.12 ± 8.34)% , (87.84 ± 12.45)% and (83.98 ± 10.37)%, respectively (P <0.05); HLA-DR increased from (13.92 ± 5.23)% to (24.26 ± 9.02)% and (30.00 ± 4.68)%, respectively (P <0.005). There was no significant change in B7-1 (2.42 ± 1.28)%, 1.91 ± 2.71%, 3.33 ± 3.92% and 2.62 ± 1.27% > 0.05); B7-2 increased from (1.28 ± 0.81)% to (3.01 ± 2.44)%, (4.62 ± 2.81)% and (8.68 ± 4.45)%, respectively, when untreated (P <0.05). The average relative fluorescence intensity (RLFI) showed the most obvious change from HLA-Ⅰ, from 57.77 ± 7.55 at non-treatment to 79.29 ± 8.34, 79.85 ± 10.23 and 89.85 ± 12